First Subject Enrolled
Opioid Use Disorder Trial
Semel Institute UCLA
Drug: Nantheia ATL5
July 2022
Pharmaceutical
Multiple Paths to Commercial SuccessFirst Subject Enrolled
FDA approves IND
PTSD Trial
University of Nebraska Medical Center (UNMC)
Drug: Nantheia ATL5
May 2022
First Subject Enrolled
Radiculopathic Pain Trial
NYU Langone Hospital
Drug: Nantheia A1002
March 2022
FDA Approves IND
Opioid Use Disorder Trial
Semel Institute UCLA
Drug: Nantheia ATL5
January 2022
FDA approves IND
Opioid Use Disorder Trial
Mt. Sinai
Drug: Nantheia ATL5
October 2021
IND filed with FDA
Opioid Use Disorder Trial
Semel Institute, UCLA
Drug: Nantheia ATL5
September 2021
First Subject enrolled
PTSD Trial
NYU School of Medicine
Drug: Nantheia A1002
June 2021
FDA approves IND
PTSD Trial
NYU Langone Hospital
Drug: Nantheia A1002
January 2021
FDA approves IND
Radiculopathic Pain Trial
NYU Langone Hospital
Drug: Nantheia A1002
January 2021
Dosing Completed
Phase I Clinical Study Trial
Hadassah Medical Hospital
Drug: Nantheia A1002
February 2020
Trial Initiated
Phase I Clinical Study Trial
Hadassah Medical Hospital
Drug: Nantheia A1002
January 2020